Literature DB >> 6376631

Cellular immunity induced by avirulent Salmonella in LPS-defective C3H/HeJ mice.

T K Eisenstein, L M Killar, B A Stocker, B M Sultzer.   

Abstract

An avirulent strain of Salmonella, SL3235, has been shown to confer high levels of immunity on lipopolysaccharide (LPS)-hyporesponsive C3H/HeJ mice. Immunized mice were also protected against challenge with Listeria monocytogenes, indicating that the Salmonella vaccine activates macrophages. It was shown that protection and macrophage activation occurred without correction of the LPS defect, as assessed by in vivo endotoxin toxicity, in vitro spleen cell mitogenicity, and the ability of in vivo treatment with LPS to enhance in vitro macrophage ingestion of C3b-coated erythrocytes. It is concluded that LPS responsiveness is neither a necessary nor a sufficient condition for Salmonella immunity, and that macrophage activation can apparently occur in C3H/HeJ mice in the face of a sustained LPS defect.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6376631

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  23 in total

1.  Evaluation in volunteers of a candidate live oral attenuated Salmonella typhi vector vaccine.

Authors:  D M Hone; C O Tacket; A M Harris; B Kay; G Losonsky; M M Levine
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

Review 2.  Live attenuated vaccines for invasive Salmonella infections.

Authors:  Sharon M Tennant; Myron M Levine
Journal:  Vaccine       Date:  2015-04-19       Impact factor: 3.641

Review 3.  Mouse models to assess the efficacy of non-typhoidal Salmonella vaccines: revisiting the role of host innate susceptibility and routes of challenge.

Authors:  Raphael Simon; Sharon M Tennant; James E Galen; Myron M Levine
Journal:  Vaccine       Date:  2011-05-25       Impact factor: 3.641

4.  Altered expression of the Salmonella typhimurium-specific B-cell repertoire in mice chronically treated with antibodies to immunoglobulin D.

Authors:  M J Fultz; F D Finkelman; E S Metcalf
Journal:  Infect Immun       Date:  1989-02       Impact factor: 3.441

5.  Immunological responses against Salmonella enterica serovar Typhimurium Braun lipoprotein and lipid A mutant strains in Swiss-Webster mice: potential use as live-attenuated vaccines.

Authors:  Tie Liu; Rolf König; Jian Sha; Stacy L Agar; Chien-Te K Tseng; Gary R Klimpel; Ashok K Chopra
Journal:  Microb Pathog       Date:  2007-10-06       Impact factor: 3.738

6.  Transcriptional response in the peripheral blood of patients infected with Salmonella enterica serovar Typhi.

Authors:  Lucinda J Thompson; Sarah J Dunstan; Christiane Dolecek; Tim Perkins; Deborah House; Gordon Dougan; Thi Hue Nguyen; Thi Phi La Tran; Cong Du Doan; Thi Phuong Le; Thi Dung Nguyen; Tinh Hien Tran; Jeremy J Farrar; Denise Monack; David J Lynn; Stephen J Popper; Stanley Falkow
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-11       Impact factor: 11.205

7.  Natural killer cells mediate protection induced by a Salmonella aroA mutant.

Authors:  R Schafer; T K Eisenstein
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

8.  Protection of C3H/HeJ mice from lethal Salmonella typhimurium LT2 infection by immunization with lipopolysaccharide-lipid A-associated protein complexes.

Authors:  J W Killion; D C Morrison
Journal:  Infect Immun       Date:  1986-10       Impact factor: 3.441

9.  Role of Toll-like receptor 4 in macrophage activation and tolerance during Salmonella enterica serovar Typhimurium infection.

Authors:  Qian Li; Bobby J Cherayil
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

10.  Plasmid-cured Salmonella enteritidis AL1192 as a candidate for a live vaccine.

Authors:  M Nakamura; S Sato; T Ohya; S Suzuki; S Ikeda; T Koeda
Journal:  Infect Immun       Date:  1985-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.